Abstract

Background: Escherichia coli is a major extended-spectrum β-lactamase (ESBL)–producing organism responsible for the rapid spread of antimicrobial resistance (AMR) that has compromised our ability to treat infections. Baseline data on population structure, virulence, and resistance mechanisms in E. coli lineages from developing countries such as Bangladesh are lacking.Methods: Whole-genome sequencing was performed for 46 ESBL–E. coli isolates cultured from patient samples at the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)-Dhaka. Sequence data were analyzed to glean details of AMR, virulence, and phylogenetic and molecular markers of E. coli lineages.Results: Genome comparison revealed presence of all major high-risk clones including sequence type 131 (ST131) (46%), ST405 (13%), ST648 (7%), ST410 (4.3%), ST38 (2%), ST73 (2%), and ST1193 (2%). The predominant ESBL gene and plasmid combination were blaCTX–M–15 and FII-FIA-FIB detected in diverse E. coli phylogroups and STs. The blaNDM–5 (9%) gene was present in prominent E. coli STs. One (2%) mcr-1–positive ST1011 E. coli, coharboring blaCTXM–55 gene, was detected. The extraintestinal pathogenic E. coli genotype was associated with specific E. coli lineages. The single nucleotide polymorphism (SNP)-based genome phylogeny largely showed correlation with phylogroups, serogroups, and fimH types. Majority of these isolates were susceptible to amikacin (93%), imipenem (93%), and nitrofurantoin (83%).Conclusion: Our study reveals a high diversity of E. coli lineages among ESBL-producing E. coli from Dhaka. This study suggests ongoing circulation of ST131 and all major non-ST131 high-risk clones that are strongly associated with cephalosporin resistance and virulence genes. These findings warrant prospective monitoring of high-risk clones, which would otherwise worsen the AMR crises.

Highlights

  • Infections with Escherichia coli that produce extended-spectrum β-lactamases (ESBLs) present an increasing clinical and public health threat (Mathers et al, 2015)

  • The sequence diversity of the study isolates as analyzed by in silico MLST demonstrates that the 46 ESBL–E. coli isolates belonged to 19 different STs (Figure 1)

  • Phylogrouping identified a total of six phylogroups, namely, A, B1, B2, C, D, and F, in the ESBL–E. coli isolates (Figure 1)

Read more

Summary

Introduction

Infections with Escherichia coli that produce extended-spectrum β-lactamases (ESBLs) present an increasing clinical and public health threat (Mathers et al, 2015) These bacteria are resistant to several new-generation cephalosporin agents and render them ineffective for treating infections (Pitout and Laupland, 2008). When certain pathogenic bacterial clones horizontally acquire ESBL genes, they can emerge and reemerge rapidly within the population through clonal dissemination and thereby gain local or even global predominance as international high-risk clones (Price et al, 2013) Examples of such epidemiological successful extraintestinal pathogenic E. coli (ExPEC) lineages include sequence type 131 (ST131), ST410, ST38, ST73, ST405, and ST648, which are associated with both nosocomial and community-acquired infections and are being increasingly detected from multiple origins, worldwide (Baquero et al, 2013; Shaik et al, 2017; Manges et al, 2019). Baseline data on population structure, virulence, and resistance mechanisms in E. coli lineages from developing countries such as Bangladesh are lacking

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.